NOVO.B.DK

306.95

-1.49%↓

HLUNB.DK

40.34

+3.12%↑

AMBUB.DK

81.7

-0.85%↓

NOVO.B.DK

306.95

-1.49%↓

HLUNB.DK

40.34

+3.12%↑

AMBUB.DK

81.7

-0.85%↓

NOVO.B.DK

306.95

-1.49%↓

HLUNB.DK

40.34

+3.12%↑

AMBUB.DK

81.7

-0.85%↓

NOVO.B.DK

306.95

-1.49%↓

HLUNB.DK

40.34

+3.12%↑

AMBUB.DK

81.7

-0.85%↓

NOVO.B.DK

306.95

-1.49%↓

HLUNB.DK

40.34

+3.12%↑

AMBUB.DK

81.7

-0.85%↓

Search

Coloplast A-S (Class B)

Fechado

476.5 -2.56

Visão Geral

Variação de preço das ações

24h

Atual

Mín

476.5

Máximo

489

Indicadores-chave

By Trading Economics

Rendimento

522M

1.4B

Vendas

83M

7B

P/E

Médio do Setor

27.294

121.746

EPS

6.32

Rendimento de Dividendos

4.78

Margem de lucro

19.835

Funcionários

16,983

EBITDA

309M

2.3B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+11.86% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

4.78%

2.26%

Próximos Ganhos

12 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-9.7B

109B

Abertura anterior

479.06

Fecho anterior

476.5

Coloplast A-S (Class B) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de fev. de 2026, 23:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 de fev. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 de fev. de 2026, 23:40 UTC

Conversa de Mercado

Gold Falls on Possible Position Adjustments -- Market Talk

15 de fev. de 2026, 23:06 UTC

Ganhos

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 de fev. de 2026, 23:04 UTC

Ganhos

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 de fev. de 2026, 23:04 UTC

Ganhos

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 de fev. de 2026, 23:01 UTC

Ganhos

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 de fev. de 2026, 23:01 UTC

Ganhos

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 de fev. de 2026, 22:53 UTC

Aquisições, Fusões, Aquisições de Empresas

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 de fev. de 2026, 22:53 UTC

Aquisições, Fusões, Aquisições de Empresas

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 de fev. de 2026, 22:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Qube Shareholders to Receive A$5.20/Share in Cash

15 de fev. de 2026, 22:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 de fev. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 de fev. de 2026, 22:17 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 de fev. de 2026, 22:16 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 de fev. de 2026, 22:14 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 de fev. de 2026, 22:14 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 de fev. de 2026, 20:48 UTC

Ganhos

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 de fev. de 2026, 20:47 UTC

Ganhos

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 de fev. de 2026, 20:46 UTC

Ganhos

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 de fev. de 2026, 20:45 UTC

Ganhos

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 de fev. de 2026, 20:44 UTC

Ganhos

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 de fev. de 2026, 20:44 UTC

Ganhos

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 de fev. de 2026, 20:43 UTC

Ganhos

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 de fev. de 2026, 20:42 UTC

Ganhos

BlueScope Net Debt A$2.2 Million at Dec. 31

15 de fev. de 2026, 20:42 UTC

Ganhos

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 de fev. de 2026, 20:41 UTC

Ganhos

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 de fev. de 2026, 20:40 UTC

Ganhos

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 de fev. de 2026, 20:40 UTC

Ganhos

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 de fev. de 2026, 20:39 UTC

Ganhos

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Comparação entre Pares

Variação de preço

Coloplast A-S (Class B) Previsão

Preço-alvo

By TipRanks

11.86% parte superior

Previsão para 12 meses

Média 901.38 DKK  11.86%

Máximo 1,056 DKK

Mínimo 720 DKK

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Coloplast A-S (Class B) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

8 ratings

2

Comprar

4

Manter

2

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat